(Q36595677)

15 August 2017

1 reference

title

Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists (English)

1 reference

15 August 2017

1 reference

cervix uterine cancer

1 reference

8

Jason Wright

1 reference

15 August 2017

author name string

Society of Gynecologic Oncologists Education Resource Panel Writing group

1

1 reference

15 August 2017

Yvonne Collins

2

1 reference

15 August 2017

Mark H Einstein

3

1 reference

15 August 2017

Bobbie S Gostout

4

1 reference

15 August 2017

Thomas J Herzog

5

1 reference

15 August 2017

L Stewart Massad

6

1 reference

15 August 2017

Janet S Rader

7

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

102

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

552-562

1 reference

Epidemiologic classification of human papillomavirus types associated with cervical cancer

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Trends in the incidence of invasive and in situ vulvar carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Cofactors with human papillomavirus in a population-based study of vulvar cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Correlation of histology and detection of human papillomavirus DNA in vulvar cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Social and cultural barriers to Papanicolaou test screening in an urban population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Pain predicts non-adherence to pap smear screening among middle-aged African American women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Limited English proficiency and breast and cervical cancer screening in a multiethnic population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Adding a Test for Human Papillomavirus DNA to Cervical-Cancer Screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Natural history of cervicovaginal papillomavirus infection in young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Management of women who test positive for high-risk types of human papillomavirus: the HART study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Cervical cancer incidence in Denmark over six decades (1943-2002).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Screening for cervical intraepithelial neoplasia in Dundee and Angus 1962-81 and its relation with invasive cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

The impact of screening on the incidence of cervical cancer in England and Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Does liquid-based technology really improve detection of cervical neoplasia? A prospective, randomized trial comparing the ThinPrep Pap Test with the conventional Pap Test, including follow-up of HSIL cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

The screening histories of women with invasive cervical cancer, Connecticut

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

American Cancer Society guideline for the early detection of cervical neoplasia and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Screening for cervical cancer and initial treatment of patients with abnormal results from papanicolaou testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

HPV testing in primary screening of older women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Human papillomavirus DNA testing for cervical cancer screening in low-resource settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

2001 Consensus Guidelines for the management of women with cervical cytological abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Atypical squamous cells of undetermined significance in girls and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Cervical dysplasia in adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Regression of low-grade squamous intra-epithelial lesions in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

ACOG Committee Opinion #300: Cervical cancer screening in adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.07.022

10.1016/J.YGYNO.2006.07.022

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference